Sector News

Teva expects Allergan deal close any day

July 13, 2016
Life sciences

Teva and Allergan are extending the deadline once again for their $40.5 billion generics deal–but investors needn’t fear, Teva said Wednesday.

Erez Vigodman, CEO of the Israeli generics leader, told shareholders on a conference call that the company expects the delayed transaction to close any day now, commentary that put shares on the rise.

The edit, which pushes the deal deadline back to Oct. 26 from July 26, “is to give Allergan additional security,” Bernstein analyst Ronny Gal wrote in a Wednesday note to clients. Allergan is also now planning to exclude two products from the sale–Actonel and Carafate–and will cut down the amount of cash it shells out by $221 million. But “it does not mean there is a delay to the close,” Gal said.

And that’s good news for nervous investors, who have been waiting with bated breath for the deal–struck last summer–to finally wrap up. The companies originally predicted Teva would have successfully swallowed Allergan’s generics unit by this year’s Q1, but FTC scrutiny has held up the process and forced several divestments.

The agreement-tweaking came along with new guidance for 2016 through 2019, with Teva unveiling numbers Gal called “high.” The company now expects $22 billion to $22.5 billion in 2016 revenue; $25.2 billion to $26.2 billion in 2017 revenue; $25.8 billion to $26.9 billion in 2018 revenue; and $26.7 billion to $27.8 billion in 2019 revenue. It also raised its Q2 sales expectations, forecasting $4.9 billion to $5 billion–up from the $4.8 billion to $4.9 it previously predicted.

Now, it’ll be up to the Petah Tikva-based drugmaker to show it can hit its marks, Gal said–but its history doesn’t say a whole lot for that prospect.

“If Teva is able to meet the expectations they projected today, then we’ll be seeing fantastic execution. The problem is that the numbers are high vs. Teva’s trendline, and there is some degree of a ‘show me’ story based on Teva not having a very strong history of delivery,” he wrote.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”